>>Can anyone tell me more about the potential for revenue from the Serum Albuminum product(s) that GTCB is currently marketting ..... and also what is the regulatory position here ?<<
GTC’s albumin program has been de-emphasized somewhat for the time being. (I asked about this at the annual meeting.) GTC’s partner, Fresenius, has not been funding the albumin joint venture, so GTC has opted to defer program development until the ATryn situation is squared away.
Despite this temporal setback for the albumin program, there is no question that drug companies are interested in a version of human serum albumin to use as an excipient that does not have the risks of being derived from plasma. I still expect a substantial contribution to shareholder value from this program in due course.
>>To me it does look like that, GTCB must give serious consideration to a PIPE prior to EMEA approval. But I would imagine it would be at prices no worse than today's.<<
I don’t think they will (#msg-6183031), and I’ve bet Randy a bottle of wine on this. Regards, Dew
Market Data 
Markets 
AI
